Site Search

... February 22, 2024 – A new paper released today in the Journal of Clinical Oncology    finds that while incorporating pharmacogenomic (PGx) testing into cancer care can help improve patient outcomes, barriers to PGx testing, discovery, and implementation are impacting its adoption and ... from them.” ACS CAN is working to improve access to PGx testing through its state advocacy work to expand insurance coverage of comprehensive biomarker testing, which includes PGx testing. Biomarker testing is a critical step toward accessing precision medicine, including targeted therapies; however, not all patients who could benefit ...

... volunteer advocates also spoke with lawmakers about the importance of leveling the playing field when it comes to increasing access to biomarker testing. Biomarker testing is an important step to accessing precision medicine and targeted therapies, which can improve quality of life and ...

... Network (ACS CAN) urges legislators to prioritize legislation that will improve access to care for cancer patients by expanding coverage for biomarker testing. “ACS CAN calls on the legislature to increase access to biomarker testing, an essential step in accessing precision medicine treatments by ensuring state regulated health insurance, including Medicaid, ...

... lost in 2017, New York would recover definitive gaps in access to early detection services for cervical cancer.        2. Expand access to biomarker testing for patients covered by state-regulated health plans, including Medicaid. Insight gained from biomarker testing can be used to help guide medical treatment in cervical and other cancers. Biomarker testing is often used to connect patients ...